ASCO 2026 | DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi, MD, MS, Emory University, Atlanta, GA, presents final analysis data from DESTINY-Breast07 (NCT04538742), evaluating first-line trastuzumab deruxtecan (T-DXd) plus durvalumab in patients with HER2-positive unresectable or metastatic breast cancer. Results demonstrated encouraging clinical activity, with a high confirmed objective response rate and durable progression-free survival, alongside a safety profile consistent with the known profiles of each agent. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
DESTINY-Breast 07, we saw the results from the T-DXd and durvalumab arm presented at ASCO this year. The overall response rate and the progression-free survival was very promising in an unselected population. It was similar to what we have seen in the other arms with DB07 with TDXD alone, or Destiny Breast 09 with TDXT and Pertuzumab. However, the real improvement with the addition of Durvalumab was seen in an immune-enriched subgroup, which was the PD-L1 positive and the TIL high tumors, where we are seeing higher overall response rate as well as higher 24-month PFS rate, which suggests durability of response with durvalumab...
DESTINY-Breast 07, we saw the results from the T-DXd and durvalumab arm presented at ASCO this year. The overall response rate and the progression-free survival was very promising in an unselected population. It was similar to what we have seen in the other arms with DB07 with TDXD alone, or Destiny Breast 09 with TDXT and Pertuzumab. However, the real improvement with the addition of Durvalumab was seen in an immune-enriched subgroup, which was the PD-L1 positive and the TIL high tumors, where we are seeing higher overall response rate as well as higher 24-month PFS rate, which suggests durability of response with durvalumab. More trials, more randomized trials that are biomarker-selected will help definitely answer this question as to what is the additional contribution of durvalumab beyond TDXD. The patient numbers were very small in this trial to make any definitive conclusions, and we do need results from randomized trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
